Name: Spiramycin
Price: 210.00 USD

- Overview
  - Spiramycin is a broad-spectrum 16-membered ring macrolide antibiotic composed of a mixture of spiramycin I, II, and III. Spiramycin was first isolated by PINNERT-SINDICO in 1954 from Streptomyces ambofaciens.
    
    Spiramycin is a bacterial protein synthesis inhibitor, it works by irreversibly binding to the P-site on the 50s ribosome, preventing peptide bond formation and translocation. Spiramycin is effective against gram-negative and gram-positive bacteria, as well as some Toxoplasma parasites.
    
    Spiramycin has shown anti-obesity effects. In a recent study (2016), it was shown that spiramycin inhibits adipogenesis in 3T3-L1 cells and ameliorates obesity and associated metabolic indications in HFD-fed mice.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Macrolide antibiotics, like spiramycin, inhibit bacterial growth bacteriostatically by targeting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. Resistance to spiramycin is commonly attributed to mutations in 50S rRNA preventing spiramycin binding allowing the cell to synthesize proteins free of error.
- Properties
  - Alternative Name
    
    Rovamycine, Formacidine, Foromacidine, NSC 55926, Kitasamycin
    
    CAS Number
    
    8025-81-8
    
    Molecular Formula
    
    Spiramycin I: C43H74N2O14
    
    Molecular Weight
    
    Spiramycin I: 843.05
    
    Appearance
    
    White or yellowish powder
    
    Solubility
    
    Methanol: Soluble
    Water: Slightly soluble
    
    Other Properties
    
    Source: Streptomyces Ambofaciens
    PH: 8.5 - 10.5
    Assay: (On Dried Basis): Not less than 4100 IU/mg
    Heavy Metals: Not more than 20 ppm
    Loss on Drying: Not more than 3.5%
    Optical Rotation: -80.0° to -85.0°
    Identification: Positive
    
    Storage
    
    2-8°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Spiramycin is a broad-spectrum antibiotic targeting a wide range of gram-positive and gram-negative bacteria. In addition, spiramycin has demonstrated activity against Toxoplasma parasites.
    
    Microbiology Applications: Spiramycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against gram positive and gramnegative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:Staphylococcus spp. 0.031 µg/mL – 0.063 µg/mL
    Eukaryotic Cell Culture Applications: Spiramycin has shown various anti-obesity effects in 3T3-L1 preadipocytes and in mice models. Spiramycin is able to inhibit adipogenesis in 3T3-L1 preadipocytes, and reduce lipid accumulation in-vitro. Spiramycin is also able to decrease adipogenic gene expression by reducing the expression of adipogenic transcriptional factors like, PPARγ, SREBP1c, and C/EBPα, in preadipocytes. Spiramycin increases AMPK activity during early adipogensis in 3T3-L1 preadipocytes. Spiramycin ameliorates HFD-induced obesity and obesity-related parameters in C57BL/6 mice.

Datasheet

MSDS

Documents

Susceptibility and Resistance Data

Spiramycin

Spiramycin

Background

Documents

We Also Recommend

Spiramycin I

Spiramycin I